{"id":70754,"date":"2026-05-12T10:43:33","date_gmt":"2026-05-12T10:43:33","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70754"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"mazdutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/mazdutide\/","title":{"rendered":"Mazdutide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que le Mazdutide ?<\/h3>\n<p style=\"margin: 0;\"><strong>Mazdutide<\/strong> (developmental codes IBI362 \/ LY3305677) is a long-acting dual GLP-1 and glucagon receptor co-agonist peptide developed by Innovent Biologics (in-licensed from Eli Lilly). It is the first dual GLP-1\/glucagon agonist to reach Phase 3 trials in obesity and type 2 diabetes, with the glucagon component adding an energy-expenditure mechanism beyond what GLP-1-only and GLP-1\/GIP-dual peptides produce. Plasma half-life supports once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2376247-09-1 (mazdutide ; couramment cit\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Type<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Co-agoniste des r\u00e9cepteurs GLP-1 et glucagon \u00e0 action prolong\u00e9e (peptide synth\u00e9tique acyl\u00e9e ; Innovent IBI362 \/ Eli Lilly LY3305677 ; \u00e9chafaudage d\u00e9riv\u00e9 de l'oxyntomoduline)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4,865 Da (avec acylation d'acide gras ; forme mature publi\u00e9e)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Structure<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Peptide synth\u00e9tique bas\u00e9 sur l'\u00e9chafaudage naturel de l'oxyntomoduline (l'agoniste double endog\u00e8ne GLP-1\/glucagon), avec des substitutions con\u00e7ues pour la r\u00e9sistance \u00e0 la DPP-4 et une cha\u00eene acyl\u00e9e d'acide gras attach\u00e9e \u00e0 un r\u00e9sidu de lysine via un lien \u03b3-Glu. La cha\u00eene acyl\u00e9e induit une liaison r\u00e9versible \u00e0 l'albumine s\u00e9rique qui produit la demi-vie hebdomadaire prolong\u00e9e.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Poudre lyophilis\u00e9e (blanche \u00e0 blanc cass\u00e9)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (v\u00e9rifi\u00e9 par HPLC, COA sur demande)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C (r\u00e9frig\u00e9rateur) pour le stock de travail ; \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Reconstitu\u00e9 : 2\u20138 \u00b0C, \u00e0 utiliser dans ~30 jours. Prot\u00e9ger de la lumi\u00e8re. Ne pas congeler-d\u00e9congeler la solution reconstitu\u00e9e.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Eau bact\u00e9riostatique (recommand\u00e9e) ou eau st\u00e9rile pour des fen\u00eatres d'utilisation plus courtes. Les peptides acyl\u00e9s peuvent se dissoudre plus lentement \u2014 pr\u00e9voyez un temps d'\u00e9quilibration suppl\u00e9mentaire.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que le Mazdutide ?<\/h2>\n<p><strong>Mazdutide<\/strong> is a long-acting synthetic dual GLP-1 and glucagon receptor co-agonist developed under the developmental codes IBI362 (Innovent Biologics, in-licensed from Eli Lilly LY3305677). It is one of the most advanced compounds in the renewed wave of oxyntomodulin-derived dual-agonist pharmacology \u2014 an approach distinct from both the GLP-1-only programme (semaglutide) and the GLP-1\/GIP dual-agonist programme (tirzepatide). The structural inspiration is oxyntomodulin itself, a 37-amino-acid product of preproglucagon processing in intestinal L-cells that natively activates both the GLP-1 and glucagon receptors. Endogenous oxyntomodulin has very short pharmacokinetics; mazdutide engineers around this with a fatty-acid acyl tether at a lysine residue that drives reversible serum-albumin binding and extends the plasma half-life sufficiently for once-weekly subcutaneous administration in clinical studies. Mazdutide has a mature molecular weight of approximately 4,865\u00a0Da including the acyl modification. The structural scaffold preserves the dual-receptor pharmacology of oxyntomodulin while engineered substitutions confer resistance to DPP-4-mediated proteolytic cleavage that would otherwise produce rapid clearance. Mazdutide is the lead Chinese metabolic peptide programme, with Phase 3 trials (GLORY-1 in obesity, DREAMS-1 and DREAMS-2 in type 2 diabetes) reporting body-weight reductions of approximately 15\u201317% at the highest dose tier over 48 weeks. Outside China, mazdutide is <strong>non approuv\u00e9<\/strong> by the FDA, EMA, MHRA, or any other major Western regulator. In China, mazdutide has been approved by the NMPA under its initial commercial brand \u2014 making it one of the first dual-agonist incretin peptides to receive regulatory clearance for human use anywhere. For the triple-agonist comparator that adds GIP on top of the same GLP-1\/glucagon combination, see our <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">Retatrutide<\/a> page produit. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Co-agonisme double des r\u00e9cepteurs GLP-1 \/ Glucagon<\/h2>\n<p>Ce qui distingue m\u00e9caniquement le mazdutide parmi les peptides m\u00e9taboliques \u00e0 double agoniste actuels est son association de l'axe canonique de sati\u00e9t\u00e9\/glyc\u00e9mie du GLP-1 avec l' <strong>axe de d\u00e9pense \u00e9nerg\u00e9tique du r\u00e9cepteur du glucagon<\/strong> \u2014 not the GIP receptor axis used by tirzepatide. The dual-receptor profile produces complementary effects across three principal compartments documented in published studies:<\/p>\n<ul>\n<li><strong>Activation du r\u00e9cepteur GLP-1 \u2014 sati\u00e9t\u00e9, s\u00e9cr\u00e9tion d'insuline par les cellules \u03b2, vidange gastrique<\/strong> \u2014 Le mazdutide active le r\u00e9cepteur GLP-1 sur les cellules b\u00eata pancr\u00e9atiques (s\u00e9cr\u00e9tion d'insuline d\u00e9pendante du glucose), les neurones POMC de l'arc hypothalamique (signalisation centrale de sati\u00e9t\u00e9) et les aff\u00e9rences vagales gastriques (ralentissement de la vidange gastrique). Ce m\u00e9canisme recoupe celui du semaglutide et de la composante GLP-1 du tirzepatide et du retatrutide.<\/li>\n<li><strong>Activation du r\u00e9cepteur du glucagon \u2014 d\u00e9pense \u00e9nerg\u00e9tique, mobilisation des lipides h\u00e9patiques, activation du tissu adipeux brun<\/strong> \u2014 The defining feature of mazdutide is the simultaneous activation of the glucagon receptor. Glucagon-receptor agonism increases resting energy expenditure modestly, drives hepatic fatty-acid oxidation and lipid mobilisation from steatotic liver, and contributes to brown adipose tissue activation in published rodent studies. The energy-expenditure component is what distinguishes glucagon-containing multi-agonists (mazdutide, retatrutide, survodutide) from the body-weight effect of GLP-1-only and GLP-1\/GIP-dual peptides \u2014 the latter produce weight loss almost entirely through reduced energy intake, while glucagon-containing agonists add a metabolic-rate component.<\/li>\n<li><strong>\u00c9quilibre d'activit\u00e9 des r\u00e9cepteurs et le \u201c paradoxe du glucagon \u201d<\/strong> \u2014 Le d\u00e9fi pharmacologique du co-agonisme du r\u00e9cepteur du glucagon est d'obtenir un effet net b\u00e9n\u00e9fique : le glucagon seul augmente la glyc\u00e9mie en stimulant la production h\u00e9patique de glucose, ce qui aggraverait plut\u00f4t qu'am\u00e9liorerait le contr\u00f4le glyc\u00e9mique. La composante GLP-1 du mazdutide surmonte l'effet glucagon sur la glyc\u00e9mie gr\u00e2ce \u00e0 son action hypoglyc\u00e9miante dominante sur l'insuline et la suppression du glucagon dans les cellules b\u00eata et alpha, tandis que le bras glucagon pr\u00e9serve les b\u00e9n\u00e9fices de mobilisation lipidique et de d\u00e9pense \u00e9nerg\u00e9tique. La puissance relative des r\u00e9cepteurs GLP-1\/glucagon est con\u00e7ue pour favoriser un effet hypoglyc\u00e9miant net \u2014 une diff\u00e9rence importante par rapport aux agonistes triples comme <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">retatrutide<\/a> o\u00f9 le GIP contribue \u00e9galement.<\/li>\n<\/ul>\n<p>The fatty-acid acyl tether attached at a lysine residue binds reversibly to circulating serum albumin, producing a plasma depot that extends the effective half-life to support once-weekly subcutaneous dosing in clinical studies. Subcutaneous administration is the standard administration route. The mechanism for sustained-release distribution is analogous to semaglutide&#8217;s C18 and tirzepatide&#8217;s C20 fatty-acid systems but with different chain length and linker chemistry tuned to mazdutide&#8217;s dual-receptor pharmacology. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Mazdutide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 preclinical DIO rodent models, body-composition (DEXA\/MRI), food-intake assays, respiratory exchange ratio and resting energy expenditure; canonical dual GLP-1\/glucagon peptide<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 contr\u00f4le glyc\u00e9mique, substituts d'HbA1c, dynamique de suppression du glucagon, sensibilit\u00e9 \u00e0 l'insuline dans des mod\u00e8les de rongeurs sous r\u00e9gime riche en graisses et db\/db ; comparaison directe avec des agonistes simples GLP-1 et des comparateurs doubles GLP-1\/GIP<\/li>\n<li><strong>MASLD\/MASH (maladie h\u00e9patique associ\u00e9e \u00e0 la dysfonction m\u00e9tabolique)<\/strong> \u2014 contenu en triglyc\u00e9rides h\u00e9patiques, ALT\/AST, stadification de la fibrose ; int\u00e9r\u00eat particulier en raison de l'activit\u00e9 de mobilisation des lipides du bras glucagon dans le foie st\u00e9atosique<\/li>\n<li><strong>Energy-expenditure studies<\/strong> \u2014 mesure de la d\u00e9pense \u00e9nerg\u00e9tique au repos, activation du tissu adipeux brun, expression des g\u00e8nes thermog\u00e9niques ; analyse m\u00e9canistique de la composante du taux m\u00e9tabolique induite par le glucagon<\/li>\n<li><strong>Comparative dual-agonist studies<\/strong> \u2014 comparaison directe avec l'agoniste double alternatif <a href=\"https:\/\/medsbase.com\/fr\/tirzepatide\/\">Tirzepatide<\/a> (GLP-1\/GIP) et l'agoniste triple <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">Retatrutide<\/a> (GLP-1\/GIP\/glucagon); receptor-stacking strategy studies<\/li>\n<li><strong>Cardiovascular and renal studies<\/strong> \u2014 effets sur la pression art\u00e9rielle, les profils lipidiques, la progression de l'ath\u00e9roscl\u00e9rose chez les ApoE<sup>-\/-<\/sup> mod\u00e8les ; ensemble de donn\u00e9es \u00e9mergent compte tenu de la maturation en Phase 3 du mazdutide<\/li>\n<li><strong>Pharmacologie de l'axe du glucagon<\/strong> \u2014 caract\u00e9risation pharmacologique isol\u00e9e du r\u00e9cepteur du glucagon, dynamique de production h\u00e9patique de glucose, \u00e9quilibre entre suppression du glucagon et agonisme du glucagon dans les mol\u00e9cules double agonistes<\/li>\n<li><strong>Comparative incretin studies<\/strong> \u2014 comparaison avec les agonistes simples GLP-1 (<a href=\"https:\/\/medsbase.com\/fr\/semaglutide\/\">Semaglutide<\/a>), double agoniste GLP-1\/GIP (<a href=\"https:\/\/medsbase.com\/fr\/tirzepatide\/\">Tirzepatide<\/a>), et les agonistes triples GLP-1\/GIP\/glucagon (<a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">Retatrutide<\/a>).<\/li>\n<\/ul>\n<p>Pour un contexte plus large sur la place du mazdutide dans le paysage des peptides m\u00e9taboliques multi-agonistes, voir <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">Retatrutide<\/a> en tant que comparateur triple agoniste ajoutant le GIP, <a href=\"https:\/\/medsbase.com\/fr\/tirzepatide\/\">Tirzepatide<\/a> en tant qu'alternative double agoniste utilisant le GIP au lieu du glucagon, <a href=\"https:\/\/medsbase.com\/fr\/semaglutide\/\">Semaglutide<\/a> en tant que r\u00e9f\u00e9rence simple agoniste, et <a href=\"https:\/\/medsbase.com\/fr\/cagrilintide\/\">Cagrilintide<\/a> comme alternative de pharmacologie combin\u00e9e sur l'axe de l'amylin. Parcourez l'int\u00e9gralit\u00e9 de <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">catalogue de peptides<\/a> pour les compos\u00e9s associ\u00e9s. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase stocks Mazdutide in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentration du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, single-cohort protocols, titration arms<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocoles \u00e0 cycle prolong\u00e9, \u00e9tudes \u00e0 cohortes multiples, co\u00fbt le plus bas par mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 3 clinical doses are 4\u20139\u00a0mg weekly, so pharmaceutical-grade vials at 5\u00a0mg or 10\u00a0mg represent single-to-multi-week supplies of clinical-equivalent dosing for in-vivo work. Mazdutide is a comparatively scarce peptide because of structural complexity and active clinical development, which is reflected in the per-mg price relative to mature small synthetic peptides. <\/p>\n<h2>Comparaison \u2014 Mazdutide vs Retatrutide<\/h2>\n<p>Le Mazdutide et <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">Retatrutide<\/a> are the two canonical glucagon-receptor-containing multi-agonist metabolic peptides in current studies. They share the GLP-1 + glucagon backbone and differ in whether they also activate the GIP receptor \u2014 Retatrutide does (triple agonist), Mazdutide does not (dual agonist). The comparison is one of the cleanest in current metabolic-peptide pharmacology because the GLP-1 and glucagon arms are shared, isolating the contribution of the GIP component. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Mazdutide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Profil des r\u00e9cepteurs<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glucagon (double)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + glucagon (triple)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u00c9chafaudage<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">D\u00e9riv\u00e9 de l'oxyntomoduline<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">D\u00e9riv\u00e9 du GIP<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longueur<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~39 acides amin\u00e9s<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">39 acides amin\u00e9s<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Demi-vie<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Hebdomadaire (acyl\u00e9)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 jours<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>D\u00e9veloppeur \/ origine<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Innovent (IBI362) \/ Eli Lilly (LY3305677)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Eli Lilly (LY3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Statut r\u00e9glementaire<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Approuv\u00e9 en Chine (NMPA) ; en cours d'investigation ailleurs<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">En cours d'investigation (Phase 3)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Effet sur le poids corporel<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15\u201317 % (GLORY-1 Phase 3, 48 sem)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~24 % (Phase 2, 48 sem)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical studies weekly dose<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4\u20139 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u201312 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The principal pharmacological question separating the two is the value of GIP receptor activation on top of GLP-1 + glucagon. Retatrutide&#8217;s Phase 2 body-weight effect is larger, suggesting GIP adds substantial benefit, but the more selective dual-agonist profile of mazdutide produces a potentially cleaner side-effect signal that may matter for long-term tolerability studies. For glucagon-axis-specific pharmacology, mazdutide is the cleaner tool because it isolates the GLP-1 + glucagon combination without the confound of GIP. For maximum-magnitude body-weight studies, the triple-agonist <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">retatrutide<\/a> reste la r\u00e9f\u00e9rence canonique. <\/p>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> conserver les flacons lyophilis\u00e9s r\u00e9frig\u00e9r\u00e9s \u00e0 2\u20138 \u00b0C dans leur emballage d'origine pour le stock de travail \u00e0 court terme. Pour le stockage \u00e0 long terme non ouvert, congeler \u00e0 \u221220 \u00b0C. La mazdutide lyophilis\u00e9e est stable sous r\u00e9frig\u00e9ration jusqu'\u00e0 24 mois et \u00e0 \u221220 \u00b0C jusqu'\u00e0 36 mois. \u00c9viter les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation de la poudre lyophilis\u00e9e. <strong>Proc\u00e9dure de reconstitution :<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers 100\u00a0mcg; 0.2\u00a0mL delivers 500\u00a0mcg; ~1.6\u00a0mL delivers a 4\u00a0mg clinical-equivalent dose. Swirl gently \u2014 do <strong>re\u00e7oit pas<\/strong> secouez pas \u2014 et laissez reposer 5 \u00e0 10 minutes pour une dissolution compl\u00e8te (les peptides acyl\u00e9s se dissolvent plus lentement que les petits peptides non modifi\u00e9s). Une solution correctement reconstitu\u00e9e doit \u00eatre claire et incolore, sans particules visibles. <strong>Apr\u00e8s reconstitution :<\/strong> conservez au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C et utilisez dans les 30 jours pour une stabilit\u00e9 optimale. Ne congelez pas la solution reconstitu\u00e9e \u2014 les cycles de gel-d\u00e9gel d\u00e9gradent l'int\u00e9grit\u00e9 du peptide. Jetez tout flacon pr\u00e9sentant de la turbidit\u00e9, un pr\u00e9cipit\u00e9 ou une d\u00e9coloration. <\/p>\n<h2 id=\"faqs\">Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>What is Mazdutide used for in studies?<\/h3>\n<p>Mazdutide is used in studies investigating the dual GLP-1 \/ glucagon receptor co-agonist axis, obesity and body-composition regulation, type 2 diabetes preclinical models, MASLD\/MASH liver disease, energy-expenditure and thermogenesis, and comparative multi-agonist incretin pharmacology against single-agonist GLP-1, dual GLP-1\/GIP (tirzepatide), and triple GLP-1\/GIP\/glucagon (retatrutide) compounds. It is the most-cited Chinese-origin metabolic peptide in current literature. The pharmaceutical-grade mazdutide sold here is <strong>re\u00e7oit pas<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>En quoi la Mazdutide diff\u00e8re-t-elle du S\u00e9maglutide ?<\/h3>\n<p>Le S\u00e9maglutide est un agoniste simple du r\u00e9cepteur GLP-1. La Mazdutide ajoute un agonisme du r\u00e9cepteur du glucagon en plus du GLP-1. Le composant glucagon ajout\u00e9 contribue \u00e0 un m\u00e9canisme de d\u00e9pense \u00e9nerg\u00e9tique \u2014 augmentation du m\u00e9tabolisme de repos, mobilisation des lipides h\u00e9patiques et activation du tissu adipeux brun \u2014 que les agonistes GLP-1 seuls ne produisent pas. Dans des essais de Phase 3 comparables, la mazdutide produit un effet sur le poids corporel l\u00e9g\u00e8rement plus important que le s\u00e9maglutide seul (15\u201317 % contre ~15 %), mais la principale diff\u00e9rence pratique est la justification m\u00e9canistique de la perte de poids : le s\u00e9maglutide agit principalement par une r\u00e9duction de l'apport alimentaire, la mazdutide \u00e0 la fois par une r\u00e9duction de l'apport et une augmentation de la d\u00e9pense \u00e9nerg\u00e9tique. <\/p>\n<h3>En quoi la Mazdutide diff\u00e8re-t-elle du Tirzepatide ?<\/h3>\n<p>Both are dual incretin agonists, but they activate different second receptors. Tirzepatide is GLP-1 + GIP. Mazdutide is GLP-1 + glucagon. The two receptor combinations produce qualitatively different metabolic profiles: GIP (tirzepatide) adds adipocyte lipolysis under fasting conditions and modest effects on energy expenditure; glucagon (mazdutide) adds substantial energy expenditure and hepatic lipid mobilisation. Tirzepatide has the larger Phase 3 dataset and larger body-weight effect; mazdutide has the unique mechanism for MASLD\/MASH studies given the glucagon-driven hepatic lipid component. <\/p>\n<h3>En quoi le Mazdutide diff\u00e8re-t-il du Retatrutide ?<\/h3>\n<p>Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). Mazdutide is a dual agonist that shares the GLP-1 + glucagon arms but lacks the GIP component. Retatrutide&#8217;s Phase 2 body-weight effect is larger than mazdutide&#8217;s Phase 3 result, suggesting GIP receptor activation adds substantial benefit on top of GLP-1 + glucagon. For studies isolating the GLP-1 + glucagon combination specifically, mazdutide is the cleaner tool because it avoids the GIP confound; for maximum body-weight effect, retatrutide remains the canonical reference. <\/p>\n<h3>What is the typical Mazdutide dose?<\/h3>\n<p>Published preclinical and clinical studies protocols use weekly subcutaneous dosing with a titration schedule starting at 1.5\u20133\u00a0mg and increasing to maintenance doses of 4\u20139\u00a0mg weekly \u2014 the dose range used in GLORY-1 and DREAMS-1 Phase 3 trials. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 ~1.6\u00a0mL equals a 4\u00a0mg clinical-equivalent dose. <\/p>\n<h3>Le Mazdutide est-il approuv\u00e9 par la FDA ?<\/h3>\n<p>No. Mazdutide is not FDA-approved in the United States, nor is it EMA- or MHRA-approved. It has been approved by China&#8217;s NMPA for human use (one of the first dual GLP-1\/glucagon agonists to receive any regulatory approval worldwide), but Western regulatory submission is still pending or ongoing as of current literature. <\/p>\n<h3>Comment le Mazdutide doit-il \u00eatre stock\u00e9 ?<\/h3>\n<p>Flacons lyophilis\u00e9s : conserv\u00e9s au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C pour les stocks de travail \u00e0 court terme, ou \u00e0 \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Solution reconstitu\u00e9e : conserv\u00e9e au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C, \u00e0 utiliser dans les 30 jours. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation d\u00e9gradent le peptide. Prot\u00e9ger de la lumi\u00e8re directe en permanence. <\/p>\n<h3>Comment reconstituer le Mazdutide ?<\/h3>\n<p>Suivez la proc\u00e9dure de reconstitution ci-dessus. Ajoutez de l'eau bact\u00e9riostatique le long de la paroi du flacon (pas directement sur le g\u00e2teau lyophilis\u00e9), agitez doucement et laissez reposer 5 \u00e0 10 minutes pour une dissolution compl\u00e8te (les peptides acyl\u00e9s se dissolvent plus lentement que les petits peptides non modifi\u00e9s). Ne <strong>re\u00e7oit pas<\/strong> Secouez le flacon. Une solution correctement reconstitu\u00e9e est claire et incolore. Pour un flacon de 5 mg + 2,0 mL de diluant, la concentration de travail est de 2,5 mg\/mL. <\/p>\n<h3>Quelles sont les dosages disponibles chez MedsBase ?<\/h3>\n<p>MedsBase carries Mazdutide in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Pourquoi le Mazdutide active-t-il \u00e9galement le r\u00e9cepteur du glucagon ?<\/h3>\n<p>L'inspiration structurelle du Mazdutide est l'oxyntomoduline, un produit endog\u00e8ne de 37 acides amin\u00e9s issu du traitement de la pr\u00e9proglucagon dans les cellules L intestinales, qui active naturellement les r\u00e9cepteurs GLP-1 et glucagon. La pharmacologie double n'est donc pas con\u00e7ue artificiellement \u2014 elle h\u00e9rite de l'\u00e9chafaudage naturel de l'oxyntomoduline. Ce qui est con\u00e7u artificiellement, c'est la r\u00e9sistance au clivage par la DPP-4 et l'acylation par acide gras qui conf\u00e8re une demi-vie hebdomadaire, ainsi que l'ajustement fin de la puissance relative des r\u00e9cepteurs GLP-1 et glucagon pour favoriser un effet hypoglyc\u00e9miant net. <\/p>\n<h3>Le composant glucagon provoque-t-il une hyperglyc\u00e9mie ?<\/h3>\n<p>This is the classic &#8220;glucagon paradox&#8221; in dual-agonist studies. Glucagon alone raises glucose by stimulating hepatic glucose output, which would worsen rather than improve diabetes. In mazdutide, the GLP-1 component overrides this through dominant glucose-lowering action on insulin and glucagon-suppression at beta- and alpha-cells, while the glucagon arm preserves the lipid-mobilisation and energy-expenditure benefits. Published studies confirms net glucose-lowering despite glucagon receptor activation, demonstrating that the engineered GLP-1-to-glucagon potency ratio achieves the desired balance. <\/p>\n<h3>Does Mazdutide cause side reported effects?<\/h3>\n<p>Les r\u00e9sultats les plus constants concernent le syst\u00e8me gastro-intestinal, similaires \u00e0 ceux d'autres peptides de l'axe GLP-1 \u2014 naus\u00e9es, suppression transitoire de l'app\u00e9tit et vidange gastrique retard\u00e9e sont dose-d\u00e9pendants et tendent \u00e0 s'att\u00e9nuer apr\u00e8s 4\u20138 semaines de dosage continu avec le d\u00e9veloppement d'une tachyphylaxie des r\u00e9cepteurs. Les effets li\u00e9s au composant glucagon incluent des \u00e9l\u00e9vations modestes de la fr\u00e9quence cardiaque au repos et (rarement) des effets transitoires sur la pression art\u00e9rielle. Les donn\u00e9es de s\u00e9curit\u00e9 \u00e0 long terme continuent de s'accumuler \u00e0 partir des essais de Phase 3 en Chine et de la surveillance post-approbation. <\/p>\n<h3>Quelle est la demi-vie du Mazdutide ?<\/h3>\n<p>Mazdutide has a plasma half-life sufficient to support once-weekly subcutaneous dosing in clinical studies, achieved through reversible binding to serum albumin via the fatty-acid acyl tether. The exact half-life is somewhat shorter than semaglutide (~165 hours) but in the same once-weekly dosing regime. The dosing schedule and clinical trial design treat it as a fully once-weekly compound. <\/p>\n<h3>How long does Mazdutide take to show effects in preclinical studies?<\/h3>\n<p>Les effets pharmacodynamiques aigus sur la tol\u00e9rance au glucose et la vidange gastrique sont d\u00e9tectables quelques heures apr\u00e8s la premi\u00e8re dose. Les effets sur le poids corporel dans les mod\u00e8les de rongeurs DIO deviennent g\u00e9n\u00e9ralement statistiquement significatifs apr\u00e8s 1 \u00e0 2 semaines d'administration hebdomadaire et continuent de s'accumuler jusqu'\u00e0 8 \u00e0 16 semaines. L'effet maximal sur la composition corporelle se d\u00e9veloppe sur 16 \u00e0 24 semaines de dosage continu, refl\u00e9tant la trajectoire de la phase 3 humaine dans l'\u00e9tude GLORY-1. <\/p>\n<h3>Puis-je commander du Mazdutide pour une livraison internationale ?<\/h3>\n<p>Oui. MedsBase exp\u00e9die le Mazdutide dans le monde entier via notre r\u00e9seau d\u00e9di\u00e9 d'exp\u00e9dition de peptides. Les commandes de peptides uniquement sont \u00e9ligibles \u00e0 notre service d'exp\u00e9dition de peptides autonome. Toutes les commandes sont exp\u00e9di\u00e9es dans un emballage \u00e0 temp\u00e9rature contr\u00f4l\u00e9e avec un suivi complet et sont couvertes par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\">Politique de R\u00e9exp\u00e9ditions Garanties<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, Body-Composition, and Multi-Agonist Studies<\/h2>\n<ul>\n<li><a href=\"\/fr\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Triple agoniste GLP-1\/GIP\/glucagon \u2014 ajoute le GIP au profil de r\u00e9cepteur du Mazdutide<\/li>\n<li><a href=\"\/fr\/tirzepatide\/\"><strong>Tirzepatide<\/strong><\/a> \u2014 Agoniste double GLP-1\/GIP \u2014 alternative double-agoniste utilisant le GIP au lieu du glucagon<\/li>\n<li><a href=\"\/fr\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Agoniste simple GLP-1 \u2014 comparateur de base canonique<\/li>\n<li><a href=\"\/fr\/cagrilintide\/\"><strong>Cagrilintide<\/strong><\/a> \u2014 Analogue de l'amylin \u2014 approche alternative de pharmacologie combin\u00e9e (CagriSema)<\/li>\n<li><a href=\"\/fr\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH analog \u2014 visceral adiposity<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Pour en savoir plus<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explorez le paysage des peptides m\u00e9taboliques multi-agonistes<\/strong><\/p>\n<p style=\"margin: 0;\">Parcourez toute la <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\"><strong>catalogue de peptides<\/strong><\/a>, avec des compos\u00e9s apparent\u00e9s incluant <a href=\"https:\/\/medsbase.com\/fr\/retatrutide\/\">Retatrutide<\/a> (triple agoniste), <a href=\"https:\/\/medsbase.com\/fr\/tirzepatide\/\">Tirzepatide<\/a> (double agoniste GLP-1\/GIP), et <a href=\"https:\/\/medsbase.com\/fr\/semaglutide\/\">Semaglutide<\/a> (agoniste unique). Guide comparatif : <a href=\"https:\/\/medsbase.com\/fr\/retatrutide-vs-tirzepatide\/\">Retatrutide vs Tirzepatide \u2014 triple agoniste vs double agoniste<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Double agoniste des r\u00e9cepteurs GLP-1 + glucagon<br \/>\n\u2705 Structure d\u00e9riv\u00e9e de l'oxyntomoduline (IBI362 \/ LY3305677)<br \/>\n\u2705 Ajoute un m\u00e9canisme de d\u00e9pense \u00e9nerg\u00e9tique au-del\u00e0 du GLP-1 seul<br \/>\n\u2705 Approuv\u00e9 en Chine ; en cours d'\u00e9tude en Occident<br \/>\n\u2705 Posologie hebdomadaire<\/p>\n<p><strong>Mazdutide<\/strong> contient un compos\u00e9 peptidique synth\u00e9tique.<\/p>","protected":false},"featured_media":70965,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6285,5441],"class_list":["post-70754","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-mazdutide","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/70754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=70754"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/70965"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=70754"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=70754"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=70754"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=70754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}